Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.32 |
| ▸ | FYN | P06241 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | CMA1 | P23946 | 2/20 | 0.32 |
| ▸ | CTRC | Q99895 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135184 | 0.94 | TSHR (0.38) | TSHRC5AR1PGRPDE4BFYN | |
| SCHEMBL5134818 | 0.90 | TSHR (0.39) | TSHRC5AR1PDE4BTLR7 | |
| SCHEMBL5136555 | 0.88 | CXCR3 (0.33) | TSHRC5AR1S1PR1 | |
| SCHEMBL5134955 | 0.88 | LTB4R2 (0.41) | TSHR | |
| SCHEMBL5134566 | 0.87 | TSHR (0.41) | TSHRC5AR1PDE4BHSD11B1NR1H3 | |
| SCHEMBL5137583 | 0.87 | HSP90AA1 (0.39) | TSHRTLR7NR1H3 | |
| SCHEMBL5074803 | 0.86 | MEN1 (0.36) | TSHRC5AR1TLR7 | |
| SCHEMBL5136148 | 0.85 | OPRK1 (0.40) | TSHRC5AR1PDE4BTLR7NR1H3 | |
| SCHEMBL5135943 | 0.85 | C5AR1 (0.36) | TSHRC5AR1 | |
| SCHEMBL5136262 | 0.85 | TLR7 (0.41) | CMA1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |